Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nikita N. Volkhin"'
Autor:
Alexander L. Khokhlov, Ilya I. Yaichkov, Mikhail A. Alexeev, Mikhail K. Korsakov, Anton A. Shetnev, Sergey A. Ivanovsky, Nikita N. Volkhin, Sergey S. Petukhov, Elena A. Vasilyeva
Publikováno v:
Research Results in Pharmacology, Vol 10, Iss 2, Pp 83-95 (2024)
Introduction: 3-(2-butyl-5-chloro-1H-imidazole-4-yl)-N-[4-methoxy-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2-oxazole-5-carboxamide is new antirheumatic drug. It is necessary to identify and synthesize the biotransformation products for its complete p
Externí odkaz:
https://doaj.org/article/e7d6d2c823e64610b4e5e8e9f63e46e5
Autor:
Alexander L. Khokhlov, Ilya I. Yaichkov, Anton А. Shetnev, Sergey A. Ivanovsky, Mikhail K. Korsakov, Mikhail A. Alexeev, Olga A. Gasilina, Nikita N. Volkhin, Sergey S. Petukhov
Publikováno v:
Research Results in Pharmacology, Vol 10, Iss 1, Pp 53-66 (2024)
Introduction: The determination of biotransformation products is an essential part of the preclinical trial of original medicines. These studies have not been conducted before for the new drug 5-[5-(trifluoromethyl)-1,2-oxazole-3-yl]-furan-2-sulfonam
Externí odkaz:
https://doaj.org/article/ef728f4ae0304dd09e1dfd1d51e4a270
Autor:
Mikhail K. Korsakov, Vladimir N. Fedorov, Nikolay A. Smirnov, Anton A. Shetnev, Olga V. Leonova, Nikita N. Volkhin, Aleksandr I. Andreyev
Publikováno v:
Research Results in Pharmacology, Vol 9, Iss 4, Pp 105-111 (2023)
Introduction: Rheumatoid arthritis (RА) is an immune-inflammatory disease intrinsic to up to 1.0% of the world’s population. Standard drugs for RA therapy are basic medications, glucocorticoids and non-steroid anti-inflammatory drugs, which often
Externí odkaz:
https://doaj.org/article/55138d84bf5f44ec836d70a06300475d
Autor:
Alexander L. Khokhlov, Ilya I. Yaichkov, Mikhail K. Korsakov, Anton A. Shetnev, Nikita N. Volkhin, Sergey S. Petukhov
Publikováno v:
Research Results in Pharmacology, Vol 9, Iss 4, Pp 53-64 (2023)
Introduction: Development of new bioanalytical methods is required for studying the systemic exposure of new selective inhibitor of carbonic anhydrase II, 4-(2-methyl-1,3-oxazole-5-yl)-benzenesulfonamide, and its N-hydroxymetabolite in plasma and in
Externí odkaz:
https://doaj.org/article/cf39056d35dc4454954dfaf8461983aa